HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis
{{output}}
Aims: Traditional breast cancer treatment relies on binary human epidermal growth factor receptor 2 (HER2) classification, while HER2-low breast cancer represents an intermediate subgroup. Given the efficacy of novel antibody-dru... ...
